Tau-Induced Damage at Hippocampal Tripartite Synapses
About the Research Project
Program
Award Type
Standard
Award Amount
$300,000
Active Dates
July 01, 2018 - June 30, 2022
Grant ID
A2018816S
Co-Principal Investigator(s)
Russell Nicholls, PhD, Columbia University
Goals
The cognitive and behavioral symptoms that characterize Alzheimer’s disease (AD) are thought to result from impaired communication between neurons in the brain at connections called synapses. Toxic forms of a protein called tau play a central role in AD and other neurodegenerative conditions, and recent data show that tau can interfere with synapses in multiple ways. These observations greatly underscore efforts to treat AD by blocking the pathological actions of tau. The goal of this project is to better understand how tau interferes with synaptic function so that we can develop effective strategies to block the impairments it causes.
Summary
A combination of high tech electrophysiological and molecular biological techniques will permit the exploration of changes occurring both pre- and post-synaptically, as well as at the level of astrocytes that surround synapses following the elevation of tau protein.
Grants
Related Grants
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD